Rocket Pharma wins FDA nod for gene therapy (update)

What: Rocket Pharma has secured FDA approval for its gene therapy, RP-L102, for the treatment of Pyruvate Kinase Deficiency.
Why: The approval is based on positive results from the company's Phase 3 trial, which showed a significant increase in PK activity in patients treated with RP-L102.
Signal: The FDA has granted a Priority Review designation to RP-L102, expediting the review process and indicating the agency's confidence in the therapy's potential.
Target: Rocket Pharma is planning to launch RP-L102 in the US market, with a projected annual sales target of **$500 million**.
Risk: The company's stock price may be volatile in the short term, as investors respond to the news and assess the potential risks and challenges associated with commercializing a gene therapy.